Cosolo W C, Morgan D J, Seeman E, Zimet A S, McKendrick J J, Zalcberg J R
Oncology Department, Heidelberg Repatriation Hospital, Victoria, Australia.
Anticancer Drugs. 1994 Jun;5(3):293-7. doi: 10.1097/00001813-199406000-00005.
For a number of cytotoxics, a relationship between efficacy and plasma concentrations has recently been demonstrated. Lean body mass has been demonstrated to be a useful parameter for predicting drug clearance for a number of non-cytotoxic drugs. However, the role of lean body mass in predicting drug clearance for any cytotoxic drug has not been previously reported. Our purpose was to investigate lean body mass as a predictor of epirubicin clearance. Pharmacokinetic studies were performed in 10 patients receiving single agent epirubicin. Although preliminary, this study suggests that lean body should be further evaluated and tested in dose optimization studies.
最近已证实，对于多种细胞毒性药物，疗效与血浆浓度之间存在关联。瘦体重已被证明是预测多种非细胞毒性药物药物清除率的一个有用参数。然而，此前尚无关于瘦体重在预测任何细胞毒性药物药物清除率方面作用的报道。我们的目的是研究瘦体重作为表柔比星清除率的预测指标。对10例接受单药表柔比星治疗的患者进行了药代动力学研究。尽管该研究尚属初步，但表明在剂量优化研究中应进一步评估和测试瘦体重。
